Urethral Adenocarcinoma: A Rare Malignancy With Poor Oncologic Outcomes Despite Neoadjuvant Treatment and Consolidative Therapy
Open Access
- 1 March 2025
- journal article
- research article
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 3 (3)
Abstract
Purpose: Primary urethral adenocarcinoma (PAC) is a rare malignancy associated with poor outcomes. There are 2 primary subtypes—clear cell adenocarcinoma (CCAC) and non–clear cell adenocarcinoma (nCCAC). In this study, we compare oncologic outcomes between CCAC vs nCCAC histological subtypes and describe differences in treatment modalities. Materials and Methods: We performed a retrospective review of patients diagnosed with PAC at our institution between 1993 to 2024. Survival analysis was stratified by histologic subtype (CCAC vs nCCAC) and primary treatment modality. Survival outcomes were stratified by patient age, neoadjuvant therapy (NAT), primary treatment modality, clinical stage, and histological subtype. Results: Of the 35 patients identified, the majority were female, were Black, and presented with locally advanced disease. Most of the patients were treated with radiotherapy (XRT) or surgical extirpation. There were no significant differences in clinical staging or histologic subtype between the 2 treatment modalities. Ten patients were treated with XRT, and 21 patients underwent primary surgical extirpation. Most of the patients received NAT. Locally advanced disease on final pathology was common for both histological subtypes. No patients were downstaged after surgical extirpation, despite nearly all receiving NAT. Survival was significantly better for CCAC vs nCCAC. There was no statistical difference in survival when comparing by treatment modality. Conclusions: PAC represents a rare, aggressive form of cancer. Favorable outcomes among the CCAC cohort may reflect a more favorable disease biology. Despite most of the patients receiving NAT, there were no patients with pathologic downstaging suggesting current neoadjuvant regimens are suboptimal and novel systemic strategies are needed for tumor downstaging to facilitate optimal local tumor control and improved oncologic outcomes.Keywords
This publication has 32 references indexed in Scilit:
- Progress in the treatment of urethral adenocarcinomaJournal of Cancer Research and Clinical Oncology, 2022
- Clinical features and oncological outcomes of primary female urethral cancerJournal of Surgical Oncology, 2022
- Adenocarcinoma of the urethra: A rare subtype of urethral cancerUrology Case Reports, 2021
- The epidemiology and role of surgery in the treatment of urethral clear cell carcinomaInternational Urology and Nephrology, 2019
- Current Disease Management of Primary Urethral CarcinomaEuropean Urology Focus, 2019
- Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional ExperienceClinical Genitourinary Cancer, 2018
- Neoadjuvant chemotherapy prior to radical cystectomy for muscle‐invasive bladder cancer with variant histologyCancer, 2017
- Primary Urethral Clear-Cell AdenocarcinomaThe American Journal of Pathology, 2014
- EAU Guidelines on Primary Urethral CarcinomaEuropean Urology, 2013
- Adenocarcinoma of the urethra in women. A clinicopathologic studyCancer, 1987